Transition-Metal-Free Cross-Coupling Reactions in Dynamic Thin Films To Access Pyrimidine and Quinoxaline Analogues
作者:Louisa A. Ho、Colin L. Raston、Keith A. Stubbs
DOI:10.1002/ejoc.201600830
日期:2016.12
The vortex fluidic device (VFD) is effective in modulating the synthesis of pyrimidine and quinoxaline-based compounds at room temperature and in high yield. The formation of the C–N bond occurs in the absence of a transition-metal catalyst, which avoids the contamination of the products with trace amounts of a transition metal. The systematic investigation of the operating parameters for the microfluidic
A segmented flow platform for on-demand medicinal chemistry and compound synthesis in oscillating droplets
作者:Ye-Jin Hwang、Connor W. Coley、Milad Abolhasani、Andreas L. Marzinzik、Guido Koch、Carsten Spanka、Hansjoerg Lehmann、Klavs F. Jensen
DOI:10.1039/c7cc03584e
日期:——
We report an automated flow chemistry platform that can efficiently perform a wide range of chemistries, including single/multi-phase and single/multi-step, with a reaction volume of just 14 μL. The breadth of compatible chemistries is successfully demonstrated and the desired products are characterized, isolated, and collected online by preparative HPLC/MS/ELSD.
我们报告了一个自动化的流动化学平台,该平台可以有效地执行各种化学反应,包括单相/多相和单步/多步,反应体积仅为14μL。通过制备型HPLC / MS / ELSD成功地证明了兼容化学的广度,并在线表征,分离和收集了所需的产品。
Nucleophilic aromatic substitution of heterocycles using a high-temperature and high-pressure flow reactor
作者:Manwika Charaschanya、Andrew R. Bogdan、Ying Wang、Stevan W. Djuric
DOI:10.1016/j.tetlet.2016.01.080
日期:2016.3
nucleophiles. Utilizing the Phoenix Flow Reactor™ in parallel with Design-of-Experiment software enabled rapid optimization of the SNAr protocol. This protocol facilitated efficient synthesis of a broad range of 2-aminoquinazolines, and was extended to 2-aminoquinoxalines and 2-aminobenzimidazoles.
我们在此报告的高温和高压的连续流协议来进行亲核芳香取代(S Ñ与氮亲核试剂的杂环的Ar)。通过将Phoenix Flow Reactor™与实验设计软件并行使用,可以快速优化S N Ar协议。该协议促进了广泛范围的2-氨基喹唑啉的有效合成,并扩展到2-氨基喹喔啉和2-氨基苯并咪唑。
Triazole Compounds as Lipoxygenase Inhibitors
申请人:Pelcman Benjamin
公开号:US20090186918A1
公开(公告)日:2009-07-23
There is provided compounds of formula (I) wherein W is an optionally substituted aryl or heteroaryl group, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.